Methylenetetrahydrofolate reductase (MTHFR) is a crucial enzyme involved in homocysteine/methionone metabolism. It catalyzes the conversion of 5,10methlenetetrahydrofolate in to 5methyltetrahydrofolate. A number of studies have examined the association of MTHFR A1298C polymorphism as risk factor for Alzheimer's disease (AD), but the results were contradictory. To clarify the influence of MTHFR A1298C polymorphism on Alzheimer's disease (AD), a meta-analysis of ten case-control studies was carried out. Four electronic databases were searched up to August, 2019 for suitable articles. The pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to evaluate the association. All statistical analyses were performed by MetaAnalyst program. The results of meta-analysis suggested that except allele contrast model, A1298C polymorphism is not risk for Alzheimer's disease using overall comparisons in three genetic models (C vs. A: OR= 1.26, 95%CI= 0.912-1.76, p= 0.04; CC+AC vs. AA: OR= 1.43; 95%CI= 0.85-2.44; p=0.05; CC vs. AA: OR= 1.16, 95%CI= .88-1.55, p= 0.51; AC vs. AA: 1.55; 95%CI= 0.81-2.93,p=0.07). Publication bias was absent in all five genetic models. In conclusion, results of present meta-analysis showed no significant association between MTHFR A1298C polymorphism and AD risk.
162 [20, 21] in included studies (Table 1) . Total cases genotype percentage of AA, AC and CC was 55.34%, 44.65% and 11.84% respectively. The controls genotypes percentage of AA, AC and CC were 55.34%, 44.65% and 11.84% respectively. In allele contrast (A vs C) meta-analysis, mutant C allele showed significant association with AD in random effect (OR= 1.26, 95%CI= 0.912-1.76, p= 0.04) models ( Figure 1 ). Unlike to allele contrast meta-analysis, pooled odds ratio for homozygote genotype (CC vs. AA) did not show any association with AD adopting random (OR= 1.16, 95%CI= .88-1.55, p= 0.51) effect models. Association of mutant heterozygous genotype (AC vs. AA; co-dominant model) aso did not show any association with AD using random effect models (OR= 1.55; 95%CI= 0.81-2.93). Dominant mutant genotypes (CC+AC vs. AA) showed no association with AD using random (OR= 1.43; 95%CI= 0.85-2.44; p=0.05) effect models. Allele contrast cumulative meta-analysis showed that after inclusion of Gledraltis et al. [24] study, odds ratio increased to 1.029 and after then it increased to 1.26 ( Figure 2 ). As evident by funnel plot the publication bias was not observed in any genetic model.
Figure 1. Allele Contrast (A vs C) Random Effect Forest Pot of Ten Studies

Figure 2. Allele Contrast Cumulative Meta-analysis
Discussion:
Results of present meta-analysis showed no association between MTHFR A1298C polymorphism and Alzheimer's disease. Elevated Hcy has been reported to be a risk factor for several psychiatric and neurodevelopmental disorders like neural tube defects, schizophrenia, bipolar disorder and depression. Hcy is implicated in increased oxidative stress, DNA damage, the triggering of apoptosis and excitotoxicity, all important mechanisms in neurodegeneration [27, 28] . Meta-analysis is a statistical tool, which is successfully used for the compilation of contradictory results of small effect/power case-control studies. Several meta-analysis were published which evaluated risk of small effect gene polymorphism for different disease and disorders like-epilepsy [29] , Alzheimer's disease [30] , G6PD [31] , Down syndrome [32] [33] [34] , Uterine Leiomyoma [35] , orofacial cleft [36, 37] , depression [38] , schizophrenia [39, 40] , autism [41, , male infertility [42] digestive tract cancer [43] , lung cancer [44] , endometrial cancer [45] , breast cancer [46, 47] , prostate cancer [48] , colorectal cancer [49] , and esophageal cancer [50] etc.
Limitations of the study should be acknowledged like-(i) unadjusted crude OR is used, (ii) study number (only ten studies) and sample size are small, (iii) gene-gene or gene-environment interactions may modify the AD risk and; however, such stratified analysis could not be performed owing to lack of data.
